Well this might end up being a good move here as there’s much to gain. At least invest in something that has the potential to improve and save lives rather than to over deluge us with more social software. Don’t misunderstand here, I use and like social medias and it works well for me with...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
01-06-2009
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, personalized medicine, healthcare, Biotech, Cancer, R and D, Start Ups, Venture Capital, Web 2.0
Both are still in trials but 10 months with chemotherapy versus 2.4 months could bring the drug to the front view of the public, as has been done in the past with activists groups pushing for approval of other drugs. Both are different with treatment plans and the drugs would be limited to the...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
12-04-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, healthcare, Pharma, Cancer, clinical trials, Prostate Cancer, PSA, R and D, antigen, testosterone
It is still at the mice testing stage, but 80% tested had a reversal of diabetes and in other cases it prevented the onset of diabetes. Side effects, etc. will need to be studied as well, but this looks very promising if in fact the drugs can prevent diabetes for many, especially children if their...
The National Cancer Institute has made clinical trial participation a top national priority and yet participant levels are still not perhaps where they could be. Yes, this is a big decision for any patient/physician to make as far as whether or not to enroll, but many trials are offering lifesaving...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-02-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, My Commentaries, Investors, health insurance, Pharma, Cancer, clinical trials, HMO, Pharmaceuticals, R and D, Drug Development, Cancer Institute
10 genetic mutations were found in the patient's tumor and virtually every cell in the tumor sample had nine of the mutations. “What's striking about the new research is that the scientists were able to sift through the 3 billion pairs of chemical bases that make up the human genome to...
One thing that comes to mind is what a waste of talent here. Series of events lead up to where he is today, but started when he ran out of money for his research related to the GFP gene and cancer. “Researchers worldwide now use GFP to track development of brain cells, the growth of tumors...
The UK continues to say “no” to cancer drugs due to price. If you stop and look at the prices for cancer drugs, something along the line here is going to need to balance soon. It is great and wonderful to have the R and D and great breakthroughs that are occurring almost daily, but what good does...
The costs of cancer treatment and associated drugs is rising as we all know. We are pouring money into R and D as fast as we can, and yes that does cost money, but insurers are making it hard to get insurance coverage and somewhere along the line you need to have a drug that is affordable as well...
This is a touchy subject as you don’t want to diminish any funds that are coming in, yet some type of umbrella where perhaps all are connected may not be a bad idea. As mentioned too, the groups are able to help gain research funds to innovators that may not otherwise be able to get a traditional...
Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-05-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Biotech, Cancer, FDA, Budgets, R and D, Alzheimers, Outsourcing